Drug Overview
Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.
Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.
Table of Contents
Product ProfilesProvenge: Prostate cancer
List of Figures
Figure 1: Provenge for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Provenge for prostate cancer
Figure 3: Drug assessment summary of Provenge for prostate cancer
Figure 4: Provenge sales for prostate cancer in the US, 2017-26
List of Tables
Table 1: Provenge drug profile
Table 2: Provenge pivotal Phase III data in prostate cancer
Table 3: Provenge sales for prostate cancer in the US ($m), 2017-26
